A Study of the Interaction Between BCG And MenC Immunisation: BAM (BAM)
A Pilot Study of the Impact of BCG Administration on the Immunogenicity of Serogroup C Meningococcal Conjugate Vaccine in Healthy Infants
The Bacille Calmette-Guérin (BCG) vaccine is the only vaccine licenced to prevent tuberculosis (TB). The stimulus it gives to the immune system allows it to respond more effectively to a subsequent infection with TB.
Many studies have shown that BCG is effective in reducing deaths from TB disease, particularly in children. However, there is also evidence that in countries with a relatively high death rate, BCG reduces this death rate but by more than would be expected by its effect on TB alone. This controversial but important finding warrants further and serious consideration. One possibility is that BCG, in addition to stimulating the immune system against TB, also has a positive effect on the way the immune system works more generally. This might mean a more effective response to serious infections that are completely unrelated to TB, or the ability to respond better to other routine childhood vaccines, or to maintain such responses for longer. In these examples, the timing of BCG administration in relation to other vaccines could be crucial.
This study will recruit 30 healthy babies who would not routinely be offered the BCG vaccine in the UK within the first week of life. Babies will be assigned at random to one of three groups of ten babies each. BCG will be given to one group of babies around birth, one at three months old and the last group will not get BCG during the study. Babies will stay in the study until 13 months old and have five blood tests over this period.
This preliminary study will look at the participants' blood to see if there are differences in the immune system, or its response to the MenC childhood meningitis vaccine or the pattern of genes activated after BCG has been given.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 7LE
- University of Oxford, Oxford Vaccine Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy male or female babies aged 7 days or under
- Born at term (≥ 36 completed weeks of gestation)
- Valid informed consent provided by an individual with parental responsibility (parent or legal guardian)
- Living within the Thames Valley region at enrolment without intention to move out of this region during the course of the study
- Parents or legal guardians must be aged 18 years or over
- Parent or legal guardian is able (in the Investigator's opinion) and willing to comply with all study requirements
- Parent or legal guardian consent provided for General Practitioner and consultant, if appropriate, to be notified of participation in the study
- Parent or legal guardian consent to review hospital birth records before enrolment and inform GP or Consultant of involvement in study, if appropriate
Exclusion Criteria:
Confirmed, suspected or significant risk of immunodeficiency (including but not limited to: maternal history of Human Immunodeficiency Virus infection, family history of congenital or hereditary immunodeficiency and receipt of significant immunosuppressive medication by the participant during the study, or by the mother prior to delivery)
- Receipt of BCG or another live vaccine prior to enrolment
Receipt of any vaccine, either prior to enrolment or planned during the study, except for:
- those listed in the study protocol at the times indicated
- hepatitis A or B vaccine or influenza vaccine.
- Receipt prior to enrolment, or planned receipt during the study, of monoclonal antibodies, immunoglobulin or any blood product
A baby who would normally be offered BCG at birth under current Department of Health guidance3. This means:
- babies living in an area of the UK with an annual incidence of TB >40 / 100,000 or
- babies who have a parent or grandparent who was born in a country with an annual incidence of TB >40 / 100,000
- Confirmed or suspected household contact with active TB
- Confirmed or suspected anaphylaxis to any component of BCG or other study vaccine
- Any confirmed or suspected serious medical condition (including seizures, neurological conditions, major congenital abnormalities or malignancy)
- Receipt of systemic antimicrobial medication since birth
- Parents or legal guardians should not be members of the study team or named on the study delegation log
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the potential participant (or carer) at risk because of participation in the study, or may influence the result of the study, or the potential participant's ability to participate in the study.
- A potential participant who has participated or is participating in another research study involving an investigational product
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: BCG at birth and routine vaccines
BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
|
This group will receive BCG at birth and all routine vaccinations.
Other Names:
This group will receive BCG at three months old and all routine vaccinations.
Other Names:
|
|
Experimental: BCG at 3 months old and routine vaccines
BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
|
This group will receive BCG at birth and all routine vaccinations.
Other Names:
This group will receive BCG at three months old and all routine vaccinations.
Other Names:
|
|
Experimental: Routine vaccines
NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
|
This group will receive no BCG but will receive all routine vaccinations.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
MenC-specific IgG in blood
Time Frame: 8 weeks following the dose of MenC vaccine (i.e. at 20 weeks of age if no delay in the schedule)
|
8 weeks following the dose of MenC vaccine (i.e. at 20 weeks of age if no delay in the schedule)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OVG-2013/04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Response
-
University of OxfordRecruiting
-
Inmunotek S.L.Not yet recruiting
-
Biosearch S.A.Completed
-
Mayo ClinicCompletedImmune ResponseUnited States
-
National Institute on Aging (NIA)Completed
-
Radboud University Medical CenterCompletedInnate Immune Response | Immune Tolerance
-
Gadjah Mada UniversityCompletedHumoral Immune ResponseIndonesia
-
Radboud University Medical CenterCompletedInnate Immune Response
-
Society for Applied StudiesNorwegian Institute of Public Health; Christian Medical College, Vellore, IndiaCompletedInnate Immune ResponseIndia
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
Clinical Trials on BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
-
MCM Vaccines B.V.Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi CompanyCompletedVirus Diseases | Bacterial Infections | Neisseria Meningitidis
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type bFrance, Poland
-
GlaxoSmithKlineCompletedHepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type bGermany, France, Canada
-
Dalhousie UniversityIWK Health Centre; MCM Vaccines B.V.CompletedInfant ImmunizationsCanada
-
MCM Vaccines B.V.CompletedVirus Diseases | Bacterial Infections | Neisseria Meningitidis
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type bFinland, Sweden
-
GlaxoSmithKlineCompletedInfections, Meningococcal | Meningococcal VaccinesEstonia, Germany, Spain
-
Merck Sharp & Dohme LLCCompletedMeningitis, Meningococcal | Rotavirus Infections
-
GlaxoSmithKlineCompletedNeisseria Meningitidis | Haemophilus Influenzae Type bUnited States
-
Cardica, IncCompletedHeart DiseaseUnited States